Detailed Profile
Tianyin Pharmaceutical
 |
 |
 |
Company Information
Market Cap:
$31.5 million
Cap Structure:
Shares Outstanding: 14.6 million
Fully diluted shares: 24.2 million
Warrants: 5 year 4.8 million warrants at $2.5 and 7 year 4.8 million warrants at $3.
Company Overview:
Tianyin pharmaceutical is a primary manufacturer, marketer and supplier of modernized TCM. The Company develops and manufactures a diversified portfolio consisting of 34 branded, cost-competitive modernized Traditional Chinese Medicines (TCMs) through its two GMP-certified manufacturing facilities and sells its products through an extensive nationwide distribution network managed by over 500 salespeople. Tianyin possesses a strong R&D platform supported by partnerships with leading Chinese academic institutions and has produced an extensive pipeline of 51 products including several generic western medicines in various stages of the approval process. CEO, Dr. Jiang, is a well-respected industry veteran who was CEO at Kelun Pharma Group where he built the Company from inception to become the world's largest producer of IV solution products with annual sales over $700 million. For more information visit: http://www.hcinternational.net/TYNP.asp
Growth Plan:
- Company is doubling TCM manufacturing lines and adding new markets and distributors to its portfolio.
- Tianyin would also review acquisition targets in both manufacturing and distribution complementary to their sector.
Financial Highlights:
- 2007 revenue and net income increased 51.1% to $20.4 million and 54.9% to $4.2 million.
- For nine months ended March 31, 2008 revenue and net income increased 77.4% to $24.2 million and 32.6% to $4.4 million.
- Q3 2008 revenue increased 70.9% to $9.2 million, net income decreased 10.9% to $1.3 million due to a one-time expense of going public and increased expense on R&D and marketing.
- 08 Make Good: $32.6 million in Revenue, $5.6 million in Net income
- 09 Make Good: $43.8 million in Revenue, $7.2 million in Net income
- Fiscal year end June 30
